Stanley Erck, Novavax CEO (Lee Jin-wook/Yonhap via AP Images)

FDA re­view spot­lights risk of heart in­flam­ma­tion linked to No­vavax's Covid vac­cine — shares tum­ble

Shares of No­vavax $NVAX cratered af­ter the FDA’s brief­ing pa­pers hit Fri­day morn­ing spelling out con­cerns about po­ten­tial heart safe­ty is­sues with their long-await­ed Covid …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.